|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Fluvoxamine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1A protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:15502009 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:15502009 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Fluvoxamine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Avp |
arginine vasopressin |
increases expression |
ISO |
Fluvoxamine results in increased expression of AVP protein |
CTD |
PMID:11195401 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Fluvoxamine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Fluvoxamine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Fluvoxamine results in decreased activity of CYP19A1 protein |
CTD |
PMID:26162595 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity increases response to substance |
ISO EXP |
[Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Phenacetin; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in increased chemical synthesis of Aconitine metabolite; CYP1A2 protein binds to and affects the metabolism of Fluvoxamine; Enoxacin inhibits the reaction [CYP1A2 protein affects the metabolism of Fluvoxamine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of olanzapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of Theophylline]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of Acetaminophen]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of clozapine N-oxide]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of norclozapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Caffeine CYP1A2 protein results in increased susceptibility to Fluvoxamine |
CTD |
PMID:9029748 PMID:11763009 PMID:15545309 PMID:15845683 PMID:15905806 PMID:18809730 PMID:18816299 PMID:21277363 PMID:21915887 PMID:26599973 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein |
CTD |
PMID:15967061 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects response to substance |
ISO |
HTR2A gene SNP affects the susceptibility to Fluvoxamine |
CTD |
PMID:12607287 |
|
NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA] Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Terfenadine co-treated with Fluvoxamine] binds to and results in decreased activity of KCNH2 protein; Fluvoxamine binds to and results in decreased activity of KCNH2 protein; Fluvoxamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Fluvoxamine results in decreased activity of KCNH2 protein |
CTD |
PMID:20071423 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
Fluvoxamine results in increased expression of NOS2 mRNA Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA] Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA] |
CTD |
PMID:12429386 PMID:27803785 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein |
CTD |
PMID:15967061 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
decreases activity affects response to substance |
ISO |
Fluvoxamine results in decreased activity of SCN5A protein SCN5A protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:19875396 |
|
NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP ISO |
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|